Jazz Pharmaceuticals (JAZZ) PT Lowered to $209 at Piper Sandler
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $230.93 +2.13%
Rating Summary:
32 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Rating Summary:
32 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Join SI Premium – FREE
Piper Sandler analyst David Amsellem lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $209.00 (from $212.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Goldman Sachs Upgrades Plains GP Holdings, L.P (PAGP) to Neutral
- Nomura/Instinet Downgrades T&D Holdings Inc (8795:JP) (TDHOY) to Neutral
- Citi Downgrades Ecopetrol SA (EC) to Neutral
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
